WO2023075534A1 - 복합 필러, 이를 이용한 제품 - Google Patents
복합 필러, 이를 이용한 제품 Download PDFInfo
- Publication number
- WO2023075534A1 WO2023075534A1 PCT/KR2022/016783 KR2022016783W WO2023075534A1 WO 2023075534 A1 WO2023075534 A1 WO 2023075534A1 KR 2022016783 W KR2022016783 W KR 2022016783W WO 2023075534 A1 WO2023075534 A1 WO 2023075534A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- calcium
- composite filler
- composite
- filler
- Prior art date
Links
- 239000000945 filler Substances 0.000 title claims abstract description 105
- 239000002131 composite material Substances 0.000 title claims abstract description 73
- 239000002245 particle Substances 0.000 claims abstract description 112
- 239000010954 inorganic particle Substances 0.000 claims abstract description 99
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000011575 calcium Substances 0.000 claims abstract description 78
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 78
- 239000011148 porous material Substances 0.000 claims abstract description 37
- 239000011230 binding agent Substances 0.000 claims description 22
- 239000011246 composite particle Substances 0.000 claims description 20
- 239000010839 body fluid Substances 0.000 claims description 18
- 210000001124 body fluid Anatomy 0.000 claims description 18
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 17
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 15
- 229910001424 calcium ion Inorganic materials 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 229920002674 hyaluronan Polymers 0.000 claims description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims description 11
- -1 Phosphorus ion Chemical class 0.000 claims description 9
- 230000004071 biological effect Effects 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 239000004372 Polyvinyl alcohol Substances 0.000 description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 description 18
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 238000001878 scanning electron micrograph Methods 0.000 description 17
- 238000005245 sintering Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000011163 secondary particle Substances 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000012890 simulated body fluid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Definitions
- the present invention relates to a composite filler with improved bioactivity, and a product using the same.
- a filler is a supplementary material or content injected or inserted into wrinkles or dented scars, and is widely used in human organs such as wrinkles, scars, cosmetic surgery, and vocal cords that require volume maintenance.
- Fillers are classified into permanent, semi-permanent, and temporary fillers according to the maintenance period, and specific examples include collagen, fat, hyaluronic acid, hydroxyapatite, polymethacryl, botox, and the like.
- hyaluronic acid fillers have the effect of filling the volume of the treatment area, but do not fundamentally improve skin elasticity, and the decomposition rate is too fast, so the filler maintenance period is short.
- the calcium filler has the advantage of promoting natural collagen production and has a fundamental skin improvement effect and has a long maintenance period due to its slow decomposition rate, but has the disadvantage of slow skin improvement due to its low bioactivity.
- the present invention is to provide a composite filler that improves the skin improvement effect by increasing the bioactivity of the composite filler by introducing porous inorganic particles manufactured by a method with high production efficiency into the composite filler, and is highly biodegradable so that corrective procedures can be performed. .
- the present invention is to provide a product using the composite filler with improved bioactivity.
- porous inorganic particles including a sintered body of calcium-based particles, and pores distributed in the sintered body; And a biodegradable carrier; provides a composite filler comprising a.
- a product containing the composite filler is also provided.
- first element may also be termed a second element, and similarly, a second element may be termed a first element.
- porous inorganic particles including a sintered body of calcium-based particles, and pores distributed in the sintered body; And a biodegradable carrier; may be provided with a complex filler comprising a.
- the present inventors include a sintered body of calcium-based particles and porous inorganic particles including pores distributed in the sintered body together with a biodegradable carrier, thereby improving the stability of the biodegradable carrier and the biological properties of the porous inorganic particles.
- the invention was completed after confirming through experiments that there is an effect of improving the skin itself by overcoming the limitations of single-component fillers by combining active functions and by generating natural collagen through tissue stimulation of porous inorganic particles after maintaining the initial volume.
- the porous inorganic particles have a high porosity and specific surface area compared to conventional high-density solid particles, so bioactivity is improved and the effect of rapidly inducing the treatment effect of the filler is high, and the particle production speed is fast and no additional drying process is required, resulting in high productivity.
- Production efficiency can be maximized as it is manufactured through a safe spray drying method without the risk of explosion because it is high and does not use an organic solvent.
- the composite filler of one embodiment may include a sintered body of calcium-based particles and porous inorganic particles including pores distributed in the sintered body.
- the calcium-based particles refer to particles containing a calcium element, and may be composed of only calcium elements or a mixture of calcium elements and other elements.
- the calcium-based particles may include hydroxyapatite.
- the hydroxyapatite is a calcium phosphate component that is an inorganic substance constituting the teeth and bones of the human body, and has high biostability and promotes natural collagen production to have a fundamental wrinkle improvement effect.
- the maximum diameter of the calcium-based particles may be greater than or equal to 10 nm and less than or equal to 10 ⁇ m.
- the diameter of the calcium-based particle means the distance between two points where a straight line passing through the center of gravity of the particle meets the boundary line of the particle, and the largest value among these diameters corresponds to the maximum diameter. Examples of a specific method for measuring the maximum diameter of the calcium-based particles are not particularly limited, but can be confirmed through TEM or SEM images, for example.
- the shape of the calcium-based particles is not particularly limited, and various shapes of conventionally known hydroxyapatite may be applied without limitation.
- Examples of the shape of the calcium-based particles include spherical, rod, needle, linear, plate, and sheet shapes.
- An example of a specific method for measuring the shape of the calcium-based particle is not particularly limited, but can be confirmed through, for example, TEM or SEM images.
- the calcium-based particles may have a maximum diameter of 10 nm or more and 200 nm or less, and may have a needle-like shape.
- the maximum diameter of the calcium-based particles is 10 nm or more and 200 nm or less, but the calcium-based particles have a spherical shape
- the porous inorganic particles when manufactured through the spray drying method, they are not produced in a spherical shape, but are manufactured in an amorphous shape, so that when injected into the body, the porous inorganic particles have a high A problem in which an injection force is required may occur.
- the maximum diameter of the calcium-based particles may be 100 nm or more and 10 ⁇ m or less, or 1 ⁇ m or more and 10 ⁇ m or less, and the calcium-based particles may have a spherical shape.
- the maximum diameter of the calcium-based particles is 100 nm or more and 10 ⁇ m or less, or 1 ⁇ m or more and 10 ⁇ m or less, but the shape of the calcium-based particles is not spherical, the surface roughness of the calcium-based secondary particles increases, resulting in high attention when injected into the body. Problems may arise that require input.
- the porous inorganic particles may include a sintered body of the calcium-based particles.
- the sintered body of the calcium-based particles refers to a product obtained through a high-temperature sintering process for the aggregate of the plurality of calcium-based particles.
- the sintering refers to a phenomenon in which, when powder, which is an aggregate of many particles, is heated to a temperature below the melting point, the powder melts and adheres to each other and solidifies. That is, the porous inorganic particles correspond to secondary particles obtained through sintering of calcium-based powder in which a large number of the calcium-based primary particles are gathered.
- the porous inorganic particles may include pores distributed in the sintered body. As the pores are distributed in the sintered body of the calcium-based particles, the porous inorganic particles may exhibit porosity. More specifically, the pores may be distributed inside and/or on the surface of the sintered body of calcium-based particles.
- the pore refers to an empty space inside the sintered body of calcium-based particles, and may be used in the same sense as a void, hollow, hole, void, or the like.
- “porous particles” may refer to particles having pores inside and/or on the surface of the particles.
- the porous inorganic particles contain pores distributed in the sintered body, the bioactivity of the sintered body is improved due to the increase in surface area due to the pores, so that a high skin improvement effect can be quickly displayed.
- the pores may be derived from a sintering process of the calcium-based particles. Specifically, the pores correspond to spaces formed between the calcium-based particles by adjusting sintering conditions during sintering between the calcium-based particles.
- the porous inorganic particles may include a heat treatment result of composite particles including a biocompatible binder and calcium-based particles.
- the biocompatible binder is removed by thermal decomposition, and fine pores may be introduced into the calcium-based particles while partial sintering between the calcium-based particles proceeds.
- the contents of the calcium-based particles may include all of the above-described contents of the composite filler.
- the biocompatible binder may help form a sintered body by inducing sufficient aggregation of the calcium-based particles in the composite particles in which the biocompatible binder is mixed with the calcium-based particles.
- the biocompatible binder may include at least one polymer selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose, and polyethylene glycol. That is, the biocompatible binder may include polyvinyl alcohol, polyvinylpyrrolidone, carboxymethyl cellulose, polyethylene glycol, or a polymer that is a mixture of two or more thereof.
- the biocompatible binder may be polyvinyl alcohol.
- the polyvinyl alcohol has a boiling point of 228 °C and can be removed while vaporizing at a temperature of 228 °C or higher.
- the weight average molecular weight of the biocompatible binder may be 100000 g/mol or more and 200000 g/mol or less, or 140000 g/mol or more and 190000 g/mol or less.
- a weight average molecular weight means the weight average molecular weight of polystyrene conversion measured by the GPC method.
- a conventionally known analyzer and a detector such as a differential refraction detector (Refractive Index Detector) and an analysis column may be used, and a commonly applied temperature Conditions, solvents, and flow rates can be applied.
- the evaluation temperature is 160 ° C
- 1,2,4-trichlorobenzene is used as a solvent.
- the flow rate was 1 mL / min
- the sample was prepared at a concentration of 10 mg / 10 mL, and then supplied in an amount of 200 ⁇ L, and the value of Mw could be obtained using a calibration curve formed using a polystyrene standard.
- Nine kinds of molecular weight of polystyrene standards were used: 2,000 / 10,000 / 30,000 / 70,000 / 200,000 / 700,000 / 2,000,000 / 4,000,000 / 10,000,000.
- the heat treatment of the composite particle may be a first heat treatment at a temperature of 450 ° C. or more and 550 ° C. or less, and a second heat treatment at a temperature of 600 ° C. or more and 1200 ° C. or less.
- the biocompatible binder may be vaporized and removed by thermal decomposition.
- the first heat treatment is 450 °C or more and 550 °C or less, or 480 °C or more and 520 °C or less at a heating rate of 2 °C / min or more and 8 °C / min or less, or 4 °C / min or more and 6 °C / min or less
- it may be heat-treated for 1 hour or more and 3 hours or less at a temperature of 450 ° C. or more and 550 ° C. or 480 ° C. or more and 520 ° C. or less.
- the sintering temperature is excessively reduced to less than 600 ° C in the secondary heat treatment process, it is difficult to secure sufficient strength of the sintered body, and if the sintering temperature is excessively increased to more than 1200 ° C, all pores are removed to form non-porous inorganic particles.
- the secondary heat treatment is performed by raising the temperature to a temperature of 600 ° C or more and 1200 ° C or less at a temperature increase rate of 2 ° C / min or more and 8 ° C / min or less, or 4 ° C / min or more and 6 ° C / min or less, and then 600 ° C.
- Heat treatment may be performed at a temperature of 1200 ° C or less for 1 hour or more and 3 hours or less.
- the content of the calcium-based particles is 5 parts by weight or more and 100 parts by weight or less, or 10 parts by weight or more and 90 parts by weight or less, or 12 parts by weight or more and 80 parts by weight or less, or 5 parts by weight or more. It may be 30 parts by weight or more, or 40 parts by weight or more and 100 parts by weight or less.
- the content of the calcium-based particles is excessively increased with respect to 1 part by weight of the biocompatible binder, it is difficult to form a spherical composite particle during spray drying due to a relative decrease in the weight of the binder.
- the content of the calcium-based particles is excessively reduced with respect to 1 part by weight of the biocompatible binder, the strength of the composite particles after sintering is low due to the relative decrease in weight of the calcium-based particles, so that it is difficult to maintain the shape and the shape of the particles may be distorted. .
- the content of the calcium-based particles is 5 parts by weight or more and 30 parts by weight or less, and the shape of the calcium-based particles may be needle-like.
- the maximum diameter of the acicular calcium-based particles may be greater than or equal to 10 nm and less than or equal to 200 nm.
- the content of the calcium-based particles is 40 parts by weight or more and 100 parts by weight or less, and the shape of the calcium-based particles may be spherical.
- the maximum diameter of the spherical calcium-based particles may be 100 nm or more and 10 ⁇ m or less, or 1 ⁇ m or more and 10 ⁇ m or less.
- the composite particles including the biocompatible binder and the calcium-based particles may be a spray-dried product of a composition including the biocompatible binder and the calcium-based particles.
- the spray-dried product refers to a product obtained by spray-drying a composition including a biocompatible binder and calcium-based particles.
- the spray drying process has a high particle production speed and does not require an additional drying process, so it has high productivity and does not use an organic solvent, so it is manufactured through a safe spray drying method without explosion-proof risk, thereby maximizing production efficiency.
- the shape of the composite particle is not particularly limited, but may be spherical as an example.
- An example of a specific method for measuring the shape of the composite particle is not greatly limited, but can be confirmed through an SEM image, for example.
- the average value of the maximum diameter of the composite particles may be 1 ⁇ m or more and 100 ⁇ m or less.
- the diameter of the composite particle means the distance between two points where a straight line passing through the center of gravity of the particle meets the boundary line of the particle, and the largest value among these diameters corresponds to the maximum diameter.
- the maximum diameter of a plurality of the composite particles is measured, and the arithmetic average of these measurements is referred to as the average value of the maximum diameter. Examples of specific methods for measuring the maximum diameter of the multiparticles are not greatly limited, but can be confirmed through SEM images, for example.
- the composite particle may be a group of individual particles having an average maximum diameter of 1 ⁇ m or more and 100 ⁇ m or less, and individual particles included in this group have an average maximum diameter of 1 ⁇ m or more and 100 ⁇ m or less can have More specifically, 95% or 99% of the individual particles included in the group may have a maximum diameter of 1 ⁇ m or more and 100 ⁇ m or less.
- the porous inorganic particles contained in the composite filler of one embodiment include a sintered body of calcium-based particles and pores distributed in the sintered body, so that the effect of rapidly improving the skin by improving bioactivity is improved. there is.
- the shape of the porous inorganic particles is not particularly limited, but an example is a spherical shape.
- An example of a specific method for measuring the shape of the porous inorganic particle is not greatly limited, but can be confirmed through an SEM image, for example.
- As the shape of the porous inorganic particles satisfies a spherical shape it is possible to inject into the body with a low injection force and induce a low immune response in the body.
- the specific surface area of the porous inorganic particles is greater than 0.1 m 2 /g, or 0.5 m 2 /g or more, or 1 m 2 /g or more, or 3 m 2 /g or more, or 4 m 2 /g or more, or 6 m 2 /g or more, or 10 m 2 /g or less, or greater than 0.1 m 2 /g and less than or equal to 10 m 2 /g, or 0.5 m 2 /g to 10 m 2 /g, or 1 m 2 /g to 10 m 2 /g, or 3 m 2 /g to 10 m 2 /g, or 4 m 2 /g to 10 m 2 /g, or 6 m 2 /g to 10 m 2 /g.
- the specific surface area was measured using a BET analyzer.
- the porosity and specific surface area are higher than those of conventional high-density solid particles, so that the bioactivity is improved and the effect of quickly inducing the treatment effect of the filler can be realized.
- the specific surface area of the porous inorganic particles is excessively reduced to 0.1 m 2 /g or less, the porosity and specific surface area are low like conventional high-density solid particles, so the bioactive activity is reduced and the treatment effect of the filler is reduced, resulting in a large amount.
- a problem may arise that requires particles of
- the specific surface area of the porous inorganic particles is excessively increased, the strength of the inorganic particle sintered body is lowered, which may cause a problem in which a process usable in manufacturing the composite filler is limited.
- the total pore volume of the porous inorganic particles is 0.001 cm 3 /g or more, or 0.01 cm 3 /g or more, or 0.016 cm 3 /g or more, or 0.017 cm 3 /g or more, or 0.05 cm 3 /g or less, or 0.001 cm 3 /g to 0.05 cm 3 /g, or 0.01 cm 3 /g to 0.05 cm 3 /g, or 0.016 cm 3 /g to 0.05 cm 3 /g, or 0.017 cm 3 /g to 0.05 cm 3 / g can be g.
- the total pore volume means the total volume of all pores contained in the porous inorganic particles, and was measured using a BET analyzer.
- the porosity and specific surface area are higher than those of conventional high-density solid particles, so the bioactivity is improved, so that the effect of quickly inducing the treatment effect of the filler can be realized.
- the total pore volume of the porous inorganic particles is excessively reduced to less than 0.001 cm 3 /g, etc., the bioactive activity is reduced due to the low porosity and specific surface area like conventional high-density solid particles, and the treatment effect of the filler is reduced, resulting in many Problems that require a positive amount of particles can arise.
- the total pore volume of the porous inorganic particles is excessively increased, the strength of the inorganic particle sintered body is lowered, which may cause a problem in which a process usable in manufacturing the composite filler is limited.
- the average value of the maximum diameter of the porous inorganic particles may be 1 ⁇ m to 1000 ⁇ m, or 10 ⁇ m to 100 ⁇ m, or 10 ⁇ m to 45 ⁇ m.
- the diameter of the porous inorganic particle means the distance between two points where a straight line passing through the center of gravity of the particle meets the boundary line of the particle, and the largest value among these diameters corresponds to the maximum diameter.
- the maximum diameter of each of the plurality of porous inorganic particles is measured, and a value obtained by calculating the arithmetic mean of these is referred to as the average value of the maximum diameter.
- An example of a specific method for measuring the maximum diameter of the porous inorganic particle is not greatly limited, but can be confirmed through an SEM image, for example.
- the porous inorganic particles may be a group of individual particles having an average maximum diameter of 1 ⁇ m to 1000 ⁇ m, or 10 ⁇ m to 100 ⁇ m, or 10 ⁇ m to 45 ⁇ m, and included in this group Individual particulates may have a maximum diameter on average between 1 ⁇ m and 1000 ⁇ m, or between 10 ⁇ m and 100 ⁇ m, or between 10 ⁇ m and 45 ⁇ m. More specifically, 95% or 99% of the individual particles included in the group may have a maximum diameter of 1 ⁇ m to 1000 ⁇ m, 10 ⁇ m to 100 ⁇ m, or 10 ⁇ m to 45 ⁇ m.
- the skin improvement effect can be maximized without side effects in the body and surgical pain. If the average value of the maximum diameter of the porous inorganic particles is excessively reduced to less than 1 ⁇ m, etc., a problem of causing an excessive foreign body reaction in the body may occur, while the average value of the maximum diameter of the porous inorganic particles exceeds 1000 ⁇ m, etc. When it is excessively increased, the specific surface area per particle mass decreases, which not only reduces the treatment effect, but also causes a problem of causing great pain during the treatment.
- the composite filler may include a biodegradable carrier.
- the biodegradable carrier serves as a substrate, matrix or carrier of the composite filler, and as will be described later, porous inorganic particles may be dispersed inside or outside the biodegradable carrier.
- the biodegradable carrier and the porous inorganic particles may be evenly dispersed while directly contacting the porous inorganic particles.
- the biodegradable carrier and the porous inorganic particles may be evenly distributed through physical dispersion without chemical bonding.
- the biodegradable carrier may contact the surface of the porous inorganic particle. There is no chemical bond between the porous inorganic particles and the biodegradable carrier.
- another coating layer for example, a silane coating layer
- a chemical bond is formed while the coating layer contacts the biodegradable carrier, the effect of improving the bioactivity of the composite filler by the porous inorganic particle is sufficiently realized.
- a problem that requires high injection force when injecting a filler mixed with an excessive amount of porous inorganic particles into the body may occur.
- biodegradable carrier examples include gelatin, hyaluronic acid (HA), carboxymethyl cellulose (CMC), chondroitin (sulfate), dextran (sulfate), chitosan, collagen, and carboxymethylcellulose.
- HA hyaluronic acid
- CMC carboxymethyl cellulose
- chondroitin sulfate
- dextran sulfate
- chitosan collagen, and carboxymethylcellulose.
- hyaluronic acid may be included as the biodegradable carrier.
- the hyaluronic acid is a biosynthetic natural substance that is present in a large amount in the skin of animals, etc., and is a hydrophilic substance because it contains a large number of hydroxyl groups (-OH), and acts as a moisturizing agent in the skin of animals. It is also present in human skin and has a moisturizing effect, so it is often included in cosmetics. It reacts with CD44 protein expressed in various epithelial cells and regulates various physiological functions.
- the composite filler may include 1 to 50 parts by weight, 1 to 30 parts by weight, or 1 to 10 parts by weight of the porous inorganic particles based on 100 parts by weight of the biodegradable carrier. If the content of the porous inorganic particles is excessively reduced with respect to 100 parts by weight of the biodegradable carrier, the skin improvement effect due to the bioactive ability may not appear. In addition, if the content of the porous inorganic particles is excessively increased with respect to 100 parts by weight of the biodegradable carrier, the porous inorganic particles in the composite filler are non-uniformly dispersed and it is difficult to smoothly inject them into the body.
- the complex filler has a bioactivity of 25 mg/(kg g) or more, or 30 mg/(kg g) or more, or 30.5 mg/(kg g) or more, or 35 mg/(kg g) or more according to Equation 1 below.
- Biological activity ⁇ [Calcium ion content in body fluid (mg/kg)] - [Calcium ion content in body fluid after immersing complex filler in body fluid for 8 days (mg/kg)] ⁇ /(Inorganic particle content in complex filler (g) )).
- the composite filler has a bioactivity of 15 mg/(kg g) or more, or 20 mg/(kg g) or more, or 22 mg/(kg g) or more, or 25 mg according to Equation 2 below. /(kg g) or more, or 32 mg/(kg g) or more, or 35 mg/(kg g) or more, or 100 mg/(kg g) or less, or 15 mg/(kg g) to 100 mg/(kg g), or 20 mg/(kg g) to 100 mg/(kg g), or 22 mg/(kg g) to 100 mg/(kg g), or 25 mg/(kg g) to 100 mg/(kg g), or 32 mg/(kg g) to 100 mg/(kg g), or 35 mg/(kg g) to 100 mg/( kg g).
- Biological activity ⁇ [Phosphorus ion content in body fluid (mg/kg)] - [Phosphorus ion content in body fluid after immersing complex filler in body fluid for 8 days (mg/kg)] ⁇ /(Inorganic particle content in complex filler (g) )).
- the composite filler may further include various additive components commonly included in fillers, for example, a lubricant such as glycerin, a phosphate buffer, and the like, as needed.
- a lubricant such as glycerin, a phosphate buffer, and the like, as needed.
- a product including the composite filler of one embodiment may be provided.
- Information on the composite filler includes all of the above-described information in the embodiment.
- Examples of the product are not particularly limited, and may be applied without limitation depending on the purpose of applying the filler.
- Examples of the products include food, pharmaceuticals, cosmetics, and the like.
- porous inorganic particles manufactured by a method with high production efficiency are introduced into the composite filler to increase the bioactivity of the composite filler to improve the skin improvement effect, and a composite filler that is highly biodegradable so that corrective procedures can be performed, and the same Used products may be provided.
- Example 1 shows surface and cross-sectional SEM images of porous inorganic particles obtained in Example 1.
- Figure 2 shows a SEM image of the surface of the porous inorganic particles obtained in Example 2.
- Example 3 shows surface and cross-sectional SEM images of porous inorganic particles obtained in Example 3.
- Figure 4 shows surface and cross-sectional SEM images of porous inorganic particles obtained in Example 4.
- Example 5 shows a SEM image of the surface of the porous inorganic particles obtained in Example 5.
- Polyvinyl alcohol (PVA, weight average molecular weight 146,000-186,000 Da, 99+% hydrolyzed) was stirred in water at 90 °C to prepare a 1 wt % PVA aqueous solution.
- a suspension was prepared by introducing needle-shaped hydroxyapatite (HAp) powder having a maximum diameter of 150 nm into the PVA aqueous solution so that the weight ratio of HAp/PVA satisfies 12/1.
- HAp needle-shaped hydroxyapatite
- the suspension was spray-dried (Buchi mini spray dryer B-290), and when drying was completed, particles were obtained, placed in a crucible, maintained at 500 ° C. for 2 hours in a box furnace, after removing PVA, and then dried at 1000 ° C. for 2 hours. During sintering to prepare porous inorganic particles.
- a composite filler was prepared by mixing 0.4 g of the porous inorganic particles with 9.6 g of hyaluronic acid.
- porous inorganic particles and composite fillers were prepared in the same manner as in Example 1, except that the maximum diameter of hydroxyapatite (HAp) powder was changed to 10 to 50 nm.
- HAp hydroxyapatite
- Polyvinyl alcohol (PVA, weight average molecular weight 146,000-186,000 Da, 99+% hydrolyzed) was stirred in water at 90 °C to prepare a 1 wt % PVA aqueous solution.
- a suspension was prepared by adding spherical hydroxyapatite (HAp) powder having a maximum diameter of 2.5 ⁇ m to the PVA aqueous solution so that the weight ratio of HAp/PVA satisfies 50/1.
- HAp spherical hydroxyapatite
- the suspension was spray-dried (Buchi mini spray dryer B-290), and when drying was completed, particles were obtained, placed in a crucible, maintained at 500 ° C. for 2 hours in a box furnace, after removing PVA, and then dried at 1000 ° C. for 2 hours. During sintering to prepare porous inorganic particles.
- a composite filler was prepared by mixing 0.4 g of the porous inorganic particles with 9.6 g of hyaluronic acid.
- porous inorganic particles and composite fillers were prepared in the same manner as in Example 3, except that the sintering temperature was changed to 1200 °C.
- porous inorganic particles and composite fillers were prepared in the same manner as in Example 3, except that the suspension was prepared such that the weight ratio of HAp/PVA satisfies 80/1.
- inorganic particles and composite fillers were prepared in the same manner as in Example 1, except that the sintering temperature was changed to 1200 °C.
- Example 1 0.4 g of the porous inorganic particles obtained in (1) of Example 1 was added to the 3-glycidoxypropyltrimethoxysilane solution for 30 minutes, and then cured at 70° C. for 24 hours to introduce a silane layer.
- porous inorganic particles into which the silane layer was introduced were mixed with 9.6 g of hyaluronic acid to prepare a composite filler in which a chemical bond between the silane layer and hyaluronic acid was formed.
- the maximum diameter of each 100 particles was measured through SEM images, and their arithmetic mean value was obtained.
- Biological activity ⁇ [Calcium ion content in body fluid (mg/kg)] - [Calcium ion content in body fluid after immersing complex filler in body fluid for 8 days (mg/kg)] ⁇ /(Inorganic particle content in complex filler (g) )).
- Biological activity ⁇ [Phosphorus ion content in body fluid (mg/kg)] - [Phosphorus ion content in body fluid after immersing complex filler in body fluid for 8 days (mg/kg)] ⁇ /(Inorganic particle content in complex filler (g) )).
- the Ca ion bioactivity was 30.2 mg/(kg g) to 47.2 mg/(kg g) and the P ion bioactivity was 21.9 mg/(kg g). ) to 36.1 mg/(kg g), which is greater than that of the comparative example, confirming that the bioactivity is excellent.
- the Ca ion bioactivity was 20.8 mg/(kg g)
- the Ca ion bioactivity was 22.7 mg/(kg g) and the P ion bioactivity was 13.3 mg/(kg g), which was less than that of the Example, and the bioactivity was low, improving skin. It was confirmed that the effect was poor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
구분 | HAp/PVA의 중량비율 | HAp의 최대직경 | HAp의 형상 | 소결온도 | 입자 형상 | 입자크기 (㎛) | 기공도 | 비표면적 (m2/g) | 총 기공부피 (cm3/g) |
실시예1 | 12/1 | 150 nm | 바늘형 | 1000 ℃ | 도면1 | 44 | ○ | 6 | 0.0171 |
실시예2 | 12/1 | 10~50 nm | 바늘형 | 1000 ℃ | 도면2 | 43 | ○ | 6 | 0.0169 |
실시예3 | 50/1 | 2.5 ㎛ | 구형 | 1000 ℃ | 도면3 | 42 | ○ | 5 | 0.0146 |
실시예4 | 50/1 | 2.5 ㎛ | 구형 | 1200 ℃ | 도면4 | 34 | ○ | 4 | 0.0123 |
실시예5 | 80/1 | 2.5 ㎛ | 구형 | 1000 ℃ | 도면5 | 44 | ○ | 5 | 0.0151 |
비교예1 | 12/1 | 150 nm | 바늘형 | 1200 ℃ | 도면6 | 49 | Ⅹ | 0.1 | 0.0009 |
구분 | Ca 이온 생체 활성도(mg/(kg·g)) | P 이온 생체 활성도(mg/(kg·g)) |
실시예1 | 47.2 | 36.1 |
실시예2 | 45.7 | 33.2 |
실시예3 | 30.6 | 23.6 |
실시예4 | 30.2 | 21.9 |
실시예5 | 37.3 | 30.5 |
비교예1 | 20.8 | 12.5 |
참고예1 | 22.7 | 13.3 |
Claims (20)
- 칼슘계 입자의 소결체, 및 상기 소결체에 분포한 기공을 포함한 다공성 무기입자; 및생분해성 캐리어;를 포함하는, 복합 필러.
- 제1항에 있어서,상기 복합 필러는 하기 수학식1에 의한 생체 활성도가 25 mg/(kg·g) 이상인, 복합 필러:[수학식1]생체 활성도 = {[체액 내 칼슘 이온 함량(mg/kg)] - [체액에 복합 필러를 8일간 담군 후, 체액 내 칼슘 이온 함량(mg/kg)]}/(복합 필러 내 무기입자 함량(g)).
- 제1항에 있어서,상기 복합 필러는 하기 수학식2에 의한 생체 활성도가 15 mg/(kg·g) 이상인, 복합 필러:[수학식2]생체 활성도 = {[체액 내 인 이온 함량(mg/kg)] - [체액에 복합 필러를 8일간 담군 후, 체액 내 인 이온 함량(mg/kg)]}/(복합 필러 내 무기입자 함량(g)).
- 제1항에 있어서,상기 생분해성 캐리어 내부 혹은 외부에 다공성 무기입자가 분산된, 복합 필러.
- 제1항에 있어서,상기 다공성 무기입자의 표면에 생분해성 캐리어가 접촉하는 것인, 복합 필러.
- 제1항에 있어서,상기 다공성 무기입자의 총 기공부피가 0.001 cm3/g 이상인, 복합 필러.
- 제1항에 있어서,상기 다공성 무기입자의 비표면적이 0.1 m2/g 초과인, 복합 필러.
- 제1항에 있어서,상기 다공성 무기입자의 최대직경의 평균값이 1 ㎛ 내지 1000 ㎛인, 복합 필러.
- 제1항에 있어서,상기 칼슘계 입자의 최대직경이 10 nm 이상 10 ㎛ 이하인, 복합 필러.
- 제1항에 있어서,상기 칼슘계 입자의 최대직경이 10 nm 이상 200 nm 이하이고, 칼슘계 입자의 형상이 바늘형인, 복합 필러.
- 제1항에 있어서,상기 칼슘계 입자의 최대직경이 100 nm 이상 10 ㎛ 이하이고, 칼슘계 입자의 형상이 구형인, 복합 필러.
- 제1항에 있어서,상기 칼슘계 입자는 하이드록시아파타이트를 포함하는, 복합 필러.
- 제1항에 있어서,상기 생분해성 캐리어는 히알루론산을 포함하는, 복합 필러.
- 제1항에 있어서,상기 생분해성 캐리어 100 중량부에 대하여, 상기 다공성 무기입자를 1 중량부 내지 50 중량부로 포함하는, 복합 필러.
- 제1항에 있어서,상기 다공성 무기입자는, 생체적합성 바인더 및 칼슘계 입자를 포함한 복합입자의 열처리 결과물을 포함하는, 복합 필러.
- 제15항에 있어서,상기 복합입자의 열처리는상기 복합입자를 450 ℃ 이상 550 ℃ 이하의 온도로 1차 열처리하고,600 ℃ 이상 1200 ℃ 이하의 온도로 2차 열처리하는 것인, 복합 필러.
- 제15항에 있어서,상기 생체적합성 바인더 1 중량부에 대하여, 상기 칼슘계 입자의 함량이 5 중량부 이상 100 중량부 이하인, 복합 필러.
- 제15항에 있어서,상기 복합입자의 최대직경의 평균값이 1 ㎛ 이상 100 ㎛ 이하인, 복합 필러.
- 제15항에 있어서,상기 복합입자는 생체적합성 바인더 및 칼슘계 입자를 포함한 조성물의 분무건조물인, 복합 필러.
- 제1항의 복합 필러를 포함하는, 제품.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3203845A CA3203845A1 (en) | 2021-11-01 | 2022-10-31 | Composite filler, and product using the same |
CN202280009212.9A CN116806160A (zh) | 2021-11-01 | 2022-10-31 | 复合填料和使用其的产品 |
AU2022378270A AU2022378270A1 (en) | 2021-11-01 | 2022-10-31 | Composite filler, and product using the same |
EP22887728.8A EP4252791A1 (en) | 2021-11-01 | 2022-10-31 | Composite filler and product using same |
US18/263,296 US20240099946A1 (en) | 2021-11-01 | 2022-10-31 | Composite filler, and product using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0148252 | 2021-11-01 | ||
KR20210148252 | 2021-11-01 | ||
KR10-2022-0141269 | 2022-10-28 | ||
KR1020220141269A KR20230063327A (ko) | 2021-11-01 | 2022-10-28 | 복합 필러, 이를 이용한 제품 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023075534A1 true WO2023075534A1 (ko) | 2023-05-04 |
Family
ID=86159646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/016783 WO2023075534A1 (ko) | 2021-11-01 | 2022-10-31 | 복합 필러, 이를 이용한 제품 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240099946A1 (ko) |
EP (1) | EP4252791A1 (ko) |
AU (1) | AU2022378270A1 (ko) |
CA (1) | CA3203845A1 (ko) |
WO (1) | WO2023075534A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101517691B1 (ko) * | 2013-10-22 | 2015-05-04 | 영남대학교 산학협력단 | 인산칼슘 세라믹 다공체 제조방법 |
US20160051725A1 (en) * | 2013-03-28 | 2016-02-25 | Bioalpha Corporation | Bone graft composition and preparation method thereof |
KR20190118694A (ko) * | 2018-04-10 | 2019-10-21 | 서울대학교산학협력단 | 다공성 마이크로스피어 복합체 및 이의 제조 방법 |
JP2020501702A (ja) * | 2016-12-13 | 2020-01-23 | サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation | 生分解性高分子の多孔性微粒子、及びそれを含む高分子フィラー |
KR102181033B1 (ko) * | 2020-03-31 | 2020-11-20 | 주식회사 휴메딕스 | 생분해성 고분자 미립자, 이를 포함하는 고분자 필러 및 이의 제조방법 |
-
2022
- 2022-10-31 CA CA3203845A patent/CA3203845A1/en active Pending
- 2022-10-31 WO PCT/KR2022/016783 patent/WO2023075534A1/ko active Application Filing
- 2022-10-31 US US18/263,296 patent/US20240099946A1/en active Pending
- 2022-10-31 EP EP22887728.8A patent/EP4252791A1/en active Pending
- 2022-10-31 AU AU2022378270A patent/AU2022378270A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160051725A1 (en) * | 2013-03-28 | 2016-02-25 | Bioalpha Corporation | Bone graft composition and preparation method thereof |
KR101517691B1 (ko) * | 2013-10-22 | 2015-05-04 | 영남대학교 산학협력단 | 인산칼슘 세라믹 다공체 제조방법 |
JP2020501702A (ja) * | 2016-12-13 | 2020-01-23 | サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation | 生分解性高分子の多孔性微粒子、及びそれを含む高分子フィラー |
KR20190118694A (ko) * | 2018-04-10 | 2019-10-21 | 서울대학교산학협력단 | 다공성 마이크로스피어 복합체 및 이의 제조 방법 |
KR102181033B1 (ko) * | 2020-03-31 | 2020-11-20 | 주식회사 휴메딕스 | 생분해성 고분자 미립자, 이를 포함하는 고분자 필러 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
US20240099946A1 (en) | 2024-03-28 |
CA3203845A1 (en) | 2023-05-04 |
EP4252791A1 (en) | 2023-10-04 |
AU2022378270A1 (en) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011030952A1 (ko) | 장용성 경질 캡슐용 수성 조성물, 장용성 경질 캡슐의 제조방법 및 장용성 경질 캡슐 | |
WO2018026204A1 (ko) | 과산화칼슘을 이용한 서방형 산소 방출형 in situ 가교 하이드로젤의 제조방법 및 이의 생의학적 용도 | |
Rowe et al. | Dimensionally stable and bioactive membrane for guided bone regeneration: An in vitro study | |
WO2014168307A1 (ko) | 지혈 및 상처치유용 카복시메틸셀룰로오스 폼 및 그의 제조방법 | |
EP2579853A1 (en) | Method of preparaing enteric hard capsule and enteric hard capsule prepared thereby | |
WO2019022502A1 (ko) | 생분해성 고분자 미립자의 제조 방법 및 그로부터 제조되는 생분해성 고분자 미립자 | |
WO2023075534A1 (ko) | 복합 필러, 이를 이용한 제품 | |
WO2018097425A1 (ko) | 다공성 하이드로겔 시트의 제조방법 및 그 제조방법에 의해 제조된 다공성 하이드로겔 시트 | |
EP2629800A1 (en) | Composition for enteric hard capsules, and enteric hard capsule preparedusing the composition | |
WO2014088177A1 (ko) | 헤이즈가 개선된 필름 | |
WO2023182700A1 (ko) | 다공성 무기입자, 및 이를 이용한 복합 필러, 제품 | |
WO2023027330A1 (ko) | 폴리에틸렌글리콜(peg)과 글리콜라이드(ga)를 가교제로 사용한 히알루론산(ha) 필러 조성물 및 그 제조방법 | |
WO2022231360A1 (ko) | 분해시간 조절이 가능한 색전용 수화겔 및 이의 제조방법 | |
WO2013119045A1 (ko) | 온도감응성 하이드로젤 내에서의 중간엽 줄기세포의 신경분화 및 신경분화용 조성물 | |
WO2023282413A1 (ko) | 고팽윤성 히알루론산 비드 겔 | |
WO2023282658A1 (ko) | 다중 가교된 온도감응성 하이드로겔 제조용 조성물 및 이의 용도 | |
WO2022114348A1 (ko) | 콜라겐-알지네이트 창상피복재 및 이의 제조방법 | |
WO2018186720A1 (ko) | 저분자량 히알루론산의 제조 방법 | |
KR20230063327A (ko) | 복합 필러, 이를 이용한 제품 | |
WO2014208824A1 (ko) | 표면에 생리활성 물질이 고정된 임플란트의 제조방법 및 이에 따라 제조된 임플란트 | |
WO2015167038A1 (ko) | 기계적 물성이 향상된 치과용 인상재 조성물 | |
WO2024111942A1 (ko) | 생분해성 고분자 분산체 및 이의 제조방법 | |
Yunoki et al. | Preparation and characterization of hydroxyapatite/collagen nanocomposite gel | |
WO2022114286A1 (ko) | 히알루론산염 파이버 및 이의 제조방법 | |
WO2021045362A1 (ko) | 히알루론산-카테콜 화합물을 포함한 조직재생 플랫폼 및 이의 제작방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22887728 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3203845 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280009212.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022887728 Country of ref document: EP Effective date: 20230628 |
|
ENP | Entry into the national phase |
Ref document number: 2022378270 Country of ref document: AU Date of ref document: 20221031 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18263296 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023015090 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023015090 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230727 |